110 related articles for article (PubMed ID: 28503993)
1. Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation.
Später T; Müller I; Eichler H; Menger MD; Laschke MW; Ampofo E
Platelets; 2018 May; 29(3):277-287. PubMed ID: 28503993
[TBL] [Abstract][Full Text] [Related]
2. Role of protein kinase CK2 in the dynamic interaction of platelets, leukocytes and endothelial cells during thrombus formation.
Ampofo E; Müller I; Dahmke IN; Eichler H; Montenarh M; Menger MD; Laschke MW
Thromb Res; 2015 Nov; 136(5):996-1006. PubMed ID: 26381437
[TBL] [Abstract][Full Text] [Related]
3. The Marine-Derived Triterpenoid Frondoside A Inhibits Thrombus Formation.
Ampofo E; Später T; Nalbach L; Menger MD; Laschke MW
Mar Drugs; 2020 Feb; 18(2):. PubMed ID: 32074969
[TBL] [Abstract][Full Text] [Related]
4. The Marine-Derived Kinase Inhibitor Fascaplysin Exerts Anti-Thrombotic Activity.
Ampofo E; Später T; Müller I; Eichler H; Menger MD; Laschke MW
Mar Drugs; 2015 Nov; 13(11):6774-91. PubMed ID: 26569265
[TBL] [Abstract][Full Text] [Related]
5. Gintonin modulates platelet function and inhibits thrombus formation via impaired glycoprotein VI signaling.
Irfan M; Jeong D; Saba E; Kwon HW; Shin JH; Jeon BR; Kim S; Kim SD; Lee DH; Nah SY; Rhee MH
Platelets; 2019; 30(5):589-598. PubMed ID: 29870296
[TBL] [Abstract][Full Text] [Related]
6. Tangeretin regulates platelet function through inhibition of phosphoinositide 3-kinase and cyclic nucleotide signaling.
Vaiyapuri S; Ali MS; Moraes LA; Sage T; Lewis KR; Jones CI; Gibbins JM
Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2740-9. PubMed ID: 24135020
[TBL] [Abstract][Full Text] [Related]
7. Effect of the hydrogen sulfide donor GYY4137 on platelet activation and microvascular thrombus formation in mice.
Grambow E; Mueller-Graf F; Delyagina E; Frank M; Kuhla A; Vollmar B
Platelets; 2014; 25(3):166-74. PubMed ID: 23586391
[TBL] [Abstract][Full Text] [Related]
8. Modulation of platelet activation and thrombus formation using a pan-PI3K inhibitor S14161.
Yi W; Li Q; Shen J; Ren L; Liu X; Wang Q; He S; Wu Q; Hu H; Mao X; Zhu L
PLoS One; 2014; 9(8):e102394. PubMed ID: 25115838
[TBL] [Abstract][Full Text] [Related]
9. Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase.
Liu Y; Hu M; Luo D; Yue M; Wang S; Chen X; Zhou Y; Wang Y; Cai Y; Hu X; Ke Y; Yang Z; Hu H
Arterioscler Thromb Vasc Biol; 2017 Nov; 37(11):2075-2086. PubMed ID: 28882875
[TBL] [Abstract][Full Text] [Related]
10. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
Shao Z; Bao Q; Jiang F; Qian H; Fang Q; Hu X
PLoS One; 2015; 10(7):e0132655. PubMed ID: 26204252
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G
Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
[TBL] [Abstract][Full Text] [Related]
12. Panax quinquefolium saponin combined with dual antiplatelet drugs inhibits platelet adhesion to injured HUVECs via PI3K/AKT and COX pathways.
Wang MM; Xue M; Miao Y; Kou N; Xu YG; Yang L; Zhang Y; Shi DZ
J Ethnopharmacol; 2016 Nov; 192():10-19. PubMed ID: 27401285
[TBL] [Abstract][Full Text] [Related]
13. The role of platelet and endothelial GARP in thrombosis and hemostasis.
Vermeersch E; Denorme F; Maes W; De Meyer SF; Vanhoorelbeke K; Edwards J; Shevach EM; Unutmaz D; Fujii H; Deckmyn H; Tersteeg C
PLoS One; 2017; 12(3):e0173329. PubMed ID: 28278197
[TBL] [Abstract][Full Text] [Related]
14. Neferine exerts its antithrombotic effect by inhibiting platelet aggregation and promoting dissociation of platelet aggregates.
Zhou YJ; Xiang JZ; Yuan H; Liu H; Tang Q; Hao HZ; Yin Z; Wang J; Ming ZY
Thromb Res; 2013 Aug; 132(2):202-10. PubMed ID: 23773522
[TBL] [Abstract][Full Text] [Related]
15. All-Trans Retinoic Acid Impairs Platelet Function and Thrombus Formation and Inhibits Protein Kinase CßI/δ Phosphorylation.
Luo Q; Wei G; Wang X; Xu X; Ju W; Li Z; Gardiner EE; Andrews RK; Zeng L; Xu K; Qiao J
Thromb Haemost; 2019 Oct; 119(10):1655-1664. PubMed ID: 31370073
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
17. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.
Ning C; Liang M; Liu S; Wang G; Edwards H; Xia Y; Polin L; Dyson G; Taub JW; Mohammad RM; Azmi AS; Zhao L; Ge Y
Oncotarget; 2017 Jul; 8(27):44295-44311. PubMed ID: 28574828
[TBL] [Abstract][Full Text] [Related]
18. The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential.
Barrachina MN; Izquierdo I; Hermida-Nogueira L; Morán LA; Pérez A; Arroyo AB; García-Barberá N; González-Conejero R; Troitiño S; Eble JA; Rivera J; Martínez C; Loza MI; Domínguez E; García Á
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33804911
[TBL] [Abstract][Full Text] [Related]
19. Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment.
Tullemans BME; Veninga A; Fernandez DI; Aarts MJB; Eble JA; van der Meijden PEJ; Heemskerk JWM; Kuijpers MJE
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681859
[TBL] [Abstract][Full Text] [Related]
20. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.
Kolev VN; Wright QG; Vidal CM; Ring JE; Shapiro IM; Ricono J; Weaver DT; Padval MV; Pachter JA; Xu Q
Cancer Res; 2015 Jan; 75(2):446-55. PubMed ID: 25432176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
